

The Histopathological Changes after Neoadjuvant Therapy for Rectal Carcinoma



Omer Faruk Ozkan¹, Nuri Emrah Goret² and Ceren Canbey Goret^{3*}

¹Department of General Surgery, Health Sciences University, Umraniye Research and Education Hospital, Istanbul, Turkey

²Department of General Surgery, Health Sciences University, Kartal Dr Lutfi Kırdar Research and Education Hospital, Istanbul, Turkey

³Department of Surgical Pathology, Health Sciences University, Sancaktepe Research and Education Hospital, Istanbul, Turkey

Received: 📅 August 05, 2018; Published: 📅 August 09, 2018

*Corresponding author: Ceren Canbey Goret, MD Health Sciences University, Sancaktepe Research and Education Hospital, Department of Surgical Pathology, Floor 0, Istanbul, Turkey

Abstract

Colorectal carcinomas are the third most common carcinomas in men and the second most common carcinomas in women. It has also been reported that deaths due to colorectal cancers account for approximately 9% of all cancer mortalities. Because chemotherapy, radiotherapy and/or neoadjuvant chemoradiotherapy are potentially beneficial during the preoperative period in terms of local control and sphincter-preserving surgery, they are particularly recommended for advanced stage carcinomas. With changing oncological treatments, care should be taken to ensure that the pathological staging of these cases are diligently and correctly performed, and pathological changes that may be present in the tumour after neoadjuvant therapy and staging systems have to be known.

Keywords: Low Anterior Resection; Abdominoperineal Resection; Colorectal Carcinoma; Total Mesorectal Excision; Neoadjuvant Therapy

The Histopathological Changes after Neoadjuvant Therapy for Rectal Carcinoma

Colorectal carcinomas are the third most common carcinomas in men and the second most common carcinomas in women [1]. A study conducted in 2014 has reported that there are approximately 10,000 new colon cancer cases and nearly 40,000 new rectal carcinoma cases in the United States. It has also been reported that deaths due to colorectal cancers account for approximately 9% of all cancer mortalities [2]. Because chemotherapy, radiotherapy and/or neoadjuvant chemoradiotherapy are potentially beneficial during the preoperative period in terms of local control and sphincter-preserving surgery, they are particularly recommended for advanced stage carcinomas [3]. According to the current guidelines, neoadjuvant therapy is recommended for all stage T3 rectal carcinomas extending from the muscularis propria to the perirectal fatty tissue, with lymph node or distant metastasis [4].

For the evaluation of the presence or absence of stage and lymph node metastasis during the preoperative period, endorectal ultrasound and pelvic MRI are recommended [3]. In the literature, it is mentioned that chemotherapy and radiotherapy should be

simultaneously performed for rectal carcinomas, and after the neoadjuvant treatment, an observational approach in the “wait and see before operation” approach should be adopted [5]. Although this approach has been recently proposed, a definite diagnosis of the presence of residual tumour in the rectum can be made only after a histopathological examination. We believe that this “wait and see before operation” approach will be increasingly adopted as information on the treatment protocols is applied, and the final histopathological diagnosis and regression grades of operated cases are more commonly reported in the literature.

Low anterior resection (sphincter-preserving surgery) is preferred after neoadjuvant therapy if there is tumour regression, particularly in lower rectal tumours, in terms of patient comfort and convenient surgical intervention or in some cases instead of abdominoperineal resection by performing intraoperative consultation (frozen section) of rectum distal surgical margin. With changing oncological treatments, care should be taken to ensure that the pathological staging of these cases are diligently and correctly performed, and pathological changes that may be present in the tumour after neoadjuvant therapy and staging systems have to be known. There are several classification systems

in terms of pathological staging when evaluating specimens after neoadjuvant therapy. In terms of the ease of evaluation and creating a shared convenience with clinicians, we usually evaluate our cases according to the 4-level staging system of Dworak and Rödel (Tables 1 & 2) [6,7].

Table 1: Dworak's regression grading system (6)

Grade 0	no regression
Grade 1	minor regression (dominant tumor mass with obvious fibrosis)
Grade 2	moderate regression (dominant tumor mass with obvious fibrosis)
Grade 3	good regression (dominant fibrosis outgrowing the tumor mass)
Grade 4	total regression (no viable tumor cells, only fibrotic mass)

Table 2: Rödel's regression grading system (7)

TRG 0	No regression
TRG 1	Minor regression, fibrosis in only 25% or less of the tumor mass
TRG 2	Dominant tumor mass with obvious fibrosis in 26% to 50% of the tumor mass
TRG 3	Dominant fibrosis outgrowing the tumor mass (ie, more than 50% tumor regression)
TRG4	Total regression, no viable tumor cells, only fibrotic mass

*TGR: Tumor regression grade

Following Neoadjuvant Treatment

Macroscopically, sometimes the tumour is completely regressed and tumour mass may not be seen. Mucosal flattening, mild ulcer-like areas, or bright areas due to possible mucinous pools can be seen in the old tumour area (Figure 1). Histopathologically, fibrosis is at the forefront of common changes that require attention. We present the grading system primarily by comparing fibrosis and tumour rates. Histopathological changes other than fibrosis include nuclear pleomorphism, cytoplasmic vacuolation and mucine pools [8-10]. Another important aspect of rectum specimens receiving neoadjuvant treatment is the assessment of lymph node. If there is a metastatic lymph node, then morphological changes similar to tumour regression will be observed in these nodes. Regression may develop in the regional lymph nodes in these cases receiving combined chemoradiotherapy, and secondary lymph nodes may not be detected. As the dissection of the lymph node becomes more difficult in such cases, it should be meticulously performed and methods for removing the mesorectal adipose tissue, such as methylene blue assisted lymph node dissection or acetone compression, may be performed when necessary as reported in the literature [11-14]. In our clinic, after performing necessary macroscopic sampling procedures for the tumour, we keep the mesorectal fat tissue portion overnight in alcohol, melt and harden the fat and sample a large part or sometimes all of the remaining fat tissues.




Figure 1: Rectal mucosal flattening and mucosal ulcer in the focal area in the rectum specimen with complete regression after neoadjuvant therapy

Conclusion

- Before the pathologic sampling of the specimen is performed, it is necessary to report to the pathologist whether the patient is treated using neoadjuvant therapy.
- In the evaluation of rectal carcinoma cases, a pathological evaluation, which is one of the most fundamental pillars, should be carefully and diligently performed. Each pathologic parameter should be carefully evaluated and the tumour regression grade should be reported.
- In these cases, the clinician and pathologist must work in a collaborative manner.

References

- Resch A, Schneider NI, Langner C (2015) Pathological evaluation of colorectal cancer specimens: advanced and early lesions. *Cesk Patol* 51(1): 12-22.
- Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. *CA Cancer J Clin* 64(1): 9-29
- Wang XT, Li DG, Li L, Kong FB, Pang LM, et al. (2015) Meta-analysis of oncological outcome after abdominoperineal resection or low anterior resection for lower rectal cancer. *Pathol Oncol Res* 21(1): 19-27.
- Leeds IL, Fang SH (2018) Neoadjuvant Therapy for Rectal Cancer. *Dis Colon Rectum* 61(8): 883-886.
- Willett CG (2018) Management of Locoregional Rectal Cancer. *J Natl Compr Canc Netw* 16(5S): 617-619.
- Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. *Int J Colorectal Dis* 12(1): 19-2310.
- Rödel C, Martus P, Papadopoulos T, Füzesi L, Klimpfinger M, et al. (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *J Clin Oncol* 23(34): 8688-9610.
- Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, et al. (2014) Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. *Am J Surg Pathol* 28: 215, 2004-2223.

9. Wheeler JM, Warren BF, Mortensen NJ (1999) Quantification of histologic regression of rectal cancer after irradiation: A proposal for a modified staging system. *Dis Colon Rectum* 45: 2002-1056.
10. Shia J, McManus M, Guillem JG, Leibold T, Zhou Q, et al. (2011) Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. *Am J Surg Pathol* 35(1): 127-134.
11. Märkl B, Schaller T, Krammer I, Cacchi C, Arnholdt HM, et al. (2013) Methylene blue-assisted lymph node dissection technique is not associated with an increased detection of lymph node metastases in colorectal cancer. *Mod Pathol* 26(9): 1246-1254.
12. Jass JR, O'Brien J, Riddell RH, Snover DC (2008) Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology 129(1): 13-23.
13. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, et al. (2012) Rectal cancer. *J Natl Compr Canc Netw* 10(12): 1528-1564.
14. Gehoff A, Basten O, Sprenger T, Conradi LC, Bismarck C, et al. (2012) Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. *Am J Surg Pathol* 36 (2): 202-213.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: [Submit Article](#)

DOI: [10.32474/LOJMS.2018.01.000102](https://doi.org/10.32474/LOJMS.2018.01.000102)



Lupine Online Journal of Medical Sciences

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles